BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Alane Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the sale, the insider owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

BioCryst Pharmaceuticals Stock Down 0.5%

BioCryst Pharmaceuticals stock traded down $0.05 during midday trading on Wednesday, hitting $9.16. 4,615,206 shares of the stock were exchanged, compared to its average volume of 5,081,376. The stock has a market capitalization of $2.30 billion, a PE ratio of 7.63 and a beta of 0.74. The company has a fifty day simple moving average of $7.39 and a two-hundred day simple moving average of $7.40. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.05. The company had revenue of $163.28 million for the quarter, compared to analyst estimates of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The business’s revenue for the quarter was up 209.1% compared to the same quarter last year. During the same period last year, the business posted ($0.13) earnings per share. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the subject of a number of research analyst reports. Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Evercore began coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective on the stock. HC Wainwright boosted their price objective on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Royal Bank Of Canada lowered their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $19.64.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Larson Financial Group LLC lifted its stake in BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares in the last quarter. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals during the 3rd quarter worth approximately $77,000. Farther Finance Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 8,109 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.